Regardless of exactly how IL-22 controls metabolic syndrome and regulates NLRP3 inflammasome activation, our results have revealed possible molecular mechanisms responsible for therapeutic effects of IL-22 for DKD and pointed out a comprehensive therapeutic strategy by IL-22 for DN, which is of great significance to the control of diabetic kidney complications. Here, IL22 is linked to metabolic syndrome.